Government funding for pregabalin in New Zealand

This petition made change with 156 supporters!

Pregabalin is the superior medication to the currently funded gabapentin. There are currently many patients receiving gabapentin as a form of pain relief for many neurological pain conditions. 

It is not fully known how it functions on the central nervous system as of yet. Some of its activity may involve interaction with voltage-gated calcium channels. Gabapentin binds to the α2δ subunit (1 and 2) and has been found to reduce calcium currents after chronic but not acute application via an effect on trafficking of voltage-dependent calcium channels in the central nervous system.Another possible mechanism of action is that gabapentin halts the formation of new synapses.

As a CRPS patient (currently the most painful condition known to mankind) I had received gabapentin as a form of pain relief for three years under the funded system. I was still getting pain flare ups that were lasting up to three weeks at a time. My specialist suggested that I replace two of my daily doses of gabapentin with the unfunded pregabalin. I have been on this regime for five months now and I have never had a flare up last more than three days since. 

I would love to replace my last daily dose of gabapentin with the pregabalin but the cost for two doses is $165 per month and I simply cannot afford $247.50 per month. I am sure though my pain flare ups will decrease significantly more if I was able to afford the third daily dose. 

I strongly feel that many New Zealanders would benefit greatly from pregabalin and would love to see the government back the funding for the betterment of those with chronic pain conditions. 

Please sign and share this petition so it can be forwarded to our Minister of Health, Jonathan Coleman for his consideration. 

Many thanks, Louise Brewer

Today: Louise is counting on you

Louise Brewer needs your help with “Jonathan Coleman : Government funding for pregabalin in New Zealand”. Join Louise and 155 supporters today.